Holding Our Breath for Inhale
Pulmonary delivery seems a narrow base on which to build a company; but Inhale is confident that through rigorous focus, it can construct plenty of deals on it. In the meantime, all eyes are on its insulin deal with Pfizer. That deal's success or failure--for reasons that may have nothing to do with Inhale or its technology--will either bring in partners still uncertain about the delivery system or scare them off.
You may also be interested in...
Drug delivery has seen plenty of acquisitions-but they represent two basic philosophical approaches, represented most recently by Johnson & Johnson's purchase of Alza and Inhale's acquisition of two privately-held firms, Bradford and Shearwater. The basic question: can a service model bring significant returns to a large shareholder base or will Alza's evolution into a product company define the way forward for the industry?
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.